learn RU58841
a potent but unapproved and potentially problematic topical anti-androgen
Search
forLearn
5 / 801 resultslearn Setipiprant
learn HMI-115
much-hyped research compound targeting prolactin receptor in scalp
learn nicotinamide
learn Naltrexone
Research
5 / 111 results
research Foot shock stress prolongs the telogen stage of the spontaneous hair cycle in a non‐depilated mouse model
Stress in mice delays hair growth and treatments blocking substance P can partly reverse this effect.
research Chronic Restraint Stress Inhibits Hair Growth via Substance P Mediated by Reactive Oxygen Species in Mice
Chronic stress can cause hair loss by increasing oxidative stress, but antioxidants may help.
research Mast cell deficient and neurokinin-1 receptor knockout mice are protected from stress-induced hair growth inhibition
Certain mice without specific receptors or mast cells don't lose hair from stress.
research Hair growth inhibition by psychoemotional stress: a mouse model for neural mechanisms in hair growth control
Stress can stop hair growth in mice, and treatments can reverse this effect.
research Indications for a brain‐hair follicle axis: inhibition of keratinocyte proliferation and up‐regulation of keratinocyte apoptosis in telogen hair follicles by stress and substance P
Stress can cause hair loss by negatively affecting hair follicles and this effect might be reversed with specific treatments.
Community Join
5 / 1000+ resultscommunity Kintor Phase 2 Results released KX-826 (pyrilutamide)
Kintor Pharmaceutical's Phase 2 results with the drug Pyrilutamide, a potential alternative to 5-ARI drugs like Finasteride and Dutasteride but without the side effects. It could be used in combination with other topical treatments such as Minoxidil. The safety of the drug has been demonstrated in 6 months of use, however there are still questions about long term efficacy and systemic absorption.
community FCE 28260: A Forgotten 5α-Reductase Inhibitor
FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.
community Kintors 1% Pyrilutamide comes in October/November
Kintor's 1% Pyrilutamide will be released in October/November. The user cannot tolerate finasteride.
community REVOLUTION in AUGUST: New possibilities according to Dr. Muñoz (pinacidil, cromakalim, diazoxide and nicorandil)
Dr. Muñoz's discovery suggests that targeting potassium channels in fibroblasts could reactivate hair growth, offering new treatment possibilities for alopecia. Potential strategies include using minoxidil, diazoxide, and other potassium channel openers, as well as bioelectric devices and direct growth factor applications.
community Ru58841 and pyrilutamid receptor binding affinity vs spironolactone?
Female considering adding topical anti-androgen, seeks advice on RU58841 or pyrilutamid's binding affinity compared to spironolactone.